Safety Studies of Pneumococcal Endolysins Cpl-1 and Pal

  title={Safety Studies of Pneumococcal Endolysins Cpl-1 and Pal},
  author={Marek Harhala and D. Nelson and P. Miernikiewicz and Ryan D. Heselpoth and Beata Brzezicka and J. Majewska and S. Linden and Xiaoran Shang and Aleksander Szymczak and D. Lecion and K. Marek-Bukowiec and M. Kłak and Bartosz Wojciechowicz and Karolina Lahutta and A. Konieczny and K. Dąbrowska},
Bacteriophage-derived endolysins have gained increasing attention as potent antimicrobial agents and numerous publications document the in vivo efficacy of these enzymes in various rodent models. However, little has been documented about their safety and toxicity profiles. Here, we present preclinical safety and toxicity data for two pneumococcal endolysins, Pal and Cpl-1. Microarray, and gene profiling was performed on human macrophages and pharyngeal cells exposed to 0.5 µM of each endolysin… Expand

Paper Mentions

The Advantages and Challenges of Using Endolysins in a Clinical Setting
Bacteriophage endolysins - extending their application to tissues and the bloodstream.
Endolysins as emerging alternative therapeutic agent to counter drug resistant infections.
Phage Lytic Protein LysRODI Prevents Staphylococcal Mastitis in Mice
Bacteriophage-Derived Endolysins Applied as Potent Biocontrol Agents to Enhance Food Safety


Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia*
Phage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal Bacteremia
Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia.
Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model.
Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract
Preclinical Safety Evaluation of Intravenously Administered SAL200 Containing the Recombinant Phage Endolysin SAL-1 as a Pharmaceutical Ingredient
Endolysins as antimicrobials.
Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers